USPTO Patent Application for NAD+ Concentration Support Compositions
Summary
The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.
What changed
This document is a published patent application from the USPTO detailing a novel composition for supporting nicotinamide adenine dinucleotide (NAD+) concentrations. The application, identified as US20260083765A1, outlines specific synergistic combinations of ingredients such as nicotinamide riboside, nicotinamide, nicotinic acid, B vitamins, magnesium, trans-resveratrol, and caffeine. The filing date for this application was September 20, 2024.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in the pharmaceutical and dietary supplement sectors related to NAD+ enhancement. Companies involved in the research, development, or manufacturing of related products should monitor the progress of this patent application and any subsequent granted patents, as they may impact intellectual property landscapes and market exclusivity for NAD+ boosting products.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS FOR SUPPORTING, OPTIMIZING AND/OR IMPROVING NAD+ CONCENTRATIONS AND RELATED METHODS
Application US20260083765A1 Kind: A1 Mar 26, 2026
Inventors
Gregory Kelly
Abstract
A composition for supporting nicotinamide adenine dinucleotide (NAD+) concentrations in humans is provided. The composition includes a synergistically effective amount of: nicotinamide riboside, nicotinamide and nicotinic acid; at least one of thiamin (vitamin B1), riboflavin (vitamin B2), pantothenic acid (vitamin B5), pyridoxine (vitamin B6), biotin (vitamin B7), folate (vitamin B9) and cobalamin (vitamin B12); and at least one of magnesium, trans-resveratrol and caffeine. Related methods are also provided.
CPC Classifications
A61K 31/706 A61K 31/05 A61K 31/197 A61K 31/4188 A61K 31/4415 A61K 31/455 A61K 31/51 A61K 31/522 A61K 31/525 A61K 31/714 A61K 33/06 A61K 36/064 A61P 43/00
Filing Date
2024-09-20
Application No.
18891204
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.